Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain.

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Vandelli MA, Tosi G, Duskey TJ, Forni F, Ruozi B.

Int J Pharm. 2018 May 30;543(1-2):300-310. doi: 10.1016/j.ijpharm.2018.03.061. Epub 2018 Mar 30.

PMID:
29608954
2.

Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles.

Pederzoli F, Tosi G, Genovese F, Belletti D, Vandelli MA, Ballestrazzi A, Forni F, Ruozi B.

Nanomedicine (Lond). 2018 Feb;13(4):407-422. doi: 10.2217/nnm-2017-0250. Epub 2018 Jan 18.

PMID:
29345202
3.

Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery.

Vilella A, Belletti D, Sauer AK, Hagmeyer S, Sarowar T, Masoni M, Stasiak N, Mulvihill JJE, Ruozi B, Forni F, Vandelli MA, Tosi G, Zoli M, Grabrucker AM.

J Trace Elem Med Biol. 2018 Sep;49:210-221. doi: 10.1016/j.jtemb.2017.12.006. Epub 2017 Dec 27.

PMID:
29325805
4.

Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.

Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G.

J Pharm Biomed Anal. 2018 Feb 20;150:25-32. doi: 10.1016/j.jpba.2017.11.054. Epub 2017 Nov 28.

PMID:
29202305
5.

Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA).

Citti C, Pacchetti B, Vandelli MA, Forni F, Cannazza G.

J Pharm Biomed Anal. 2018 Feb 5;149:532-540. doi: 10.1016/j.jpba.2017.11.044. Epub 2017 Nov 20.

PMID:
29182999
6.

Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders.

Duskey JT, Belletti D, Pederzoli F, Vandelli MA, Forni F, Ruozi B, Tosi G.

Int Rev Neurobiol. 2017;137:1-28. doi: 10.1016/bs.irn.2017.08.006. Epub 2017 Oct 16. Review.

PMID:
29132540
7.

Corrigendum to: EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION (International Journal of Pharmaceutics. 511 (1) (2016) 331-340).

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Cappello V, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2017 Nov 25;533(1):321. doi: 10.1016/j.ijpharm.2017.10.019. No abstract available.

PMID:
29056147
8.

A Metabolomic Approach Applied to a Liquid Chromatography Coupled to High-Resolution Tandem Mass Spectrometry Method (HPLC-ESI-HRMS/MS): Towards the Comprehensive Evaluation of the Chemical Composition of Cannabis Medicinal Extracts.

Citti C, Battisti UM, Braghiroli D, Ciccarella G, Schmid M, Vandelli MA, Cannazza G.

Phytochem Anal. 2018 Mar;29(2):144-155. doi: 10.1002/pca.2722. Epub 2017 Sep 15.

PMID:
28915313
9.

Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach.

Belletti D, Riva G, Luppi M, Tosi G, Forni F, Vandelli MA, Ruozi B, Pederzoli F.

Eur J Pharm Sci. 2017 Sep 30;107:230-239. doi: 10.1016/j.ejps.2017.07.020. Epub 2017 Jul 18.

PMID:
28728978
10.

Pharmaceutical and biomedical analysis of cannabinoids: A critical review.

Citti C, Braghiroli D, Vandelli MA, Cannazza G.

J Pharm Biomed Anal. 2018 Jan 5;147:565-579. doi: 10.1016/j.jpba.2017.06.003. Epub 2017 Jun 4. Review.

PMID:
28641906
11.

Novel Curcumin loaded nanoparticles engineered for Blood-Brain Barrier crossing and able to disrupt Abeta aggregates.

Barbara R, Belletti D, Pederzoli F, Masoni M, Keller J, Ballestrazzi A, Vandelli MA, Tosi G, Grabrucker AM.

Int J Pharm. 2017 Jun 30;526(1-2):413-424. doi: 10.1016/j.ijpharm.2017.05.015. Epub 2017 May 8.

PMID:
28495580
12.

Protein corona and nanoparticles: how can we investigate on?

Pederzoli F, Tosi G, Vandelli MA, Belletti D, Forni F, Ruozi B.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Nov;9(6). doi: 10.1002/wnan.1467. Epub 2017 Mar 15. Review.

PMID:
28296346
13.

Apoferritin nanocage as streptomycin drug reservoir: Technological optimization of a new drug delivery system.

Ruozi B, Veratti P, Vandelli MA, Tombesi A, Tonelli M, Forni F, Pederzoli F, Belletti D, Tosi G.

Int J Pharm. 2017 Feb 25;518(1-2):281-288. doi: 10.1016/j.ijpharm.2016.12.038. Epub 2016 Dec 23.

PMID:
28017769
14.

Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin.

Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G, Ruozi B.

Expert Opin Drug Deliv. 2017 Jul;14(7):825-840. doi: 10.1080/17425247.2017.1243528. Epub 2016 Oct 21. Review.

PMID:
27690258
15.

Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.

Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G.

CNS Neurol Disord Drug Targets. 2016;15(9):1079-1091. Review.

PMID:
27633786
16.

EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION.

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Cappello V, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2016 Sep 10;511(1):331-340. doi: 10.1016/j.ijpharm.2016.07.022. Epub 2016 Jul 12.

PMID:
27418565
17.

Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method.

Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G.

J Pharm Biomed Anal. 2016 Sep 5;128:201-209. doi: 10.1016/j.jpba.2016.05.033. Epub 2016 May 20.

PMID:
27268223
18.

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.

Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, Marin O, Vandelli MA, Forni F, Scarpa M, Tomanin R, Tosi G.

PLoS One. 2016 May 26;11(5):e0156452. doi: 10.1371/journal.pone.0156452. eCollection 2016.

19.

Nanoparticle transport across the blood brain barrier.

Grabrucker AM, Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G.

Tissue Barriers. 2016 Feb 25;4(1):e1153568. doi: 10.1080/21688370.2016.1153568. eCollection 2016 Jan-Mar. Review.

20.

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.

Belletti D, Tosi G, Forni F, Lagreca I, Barozzi P, Pederzoli F, Vandelli MA, Riva G, Luppi M, Ruozi B.

Eur J Pharm Biopharm. 2016 Feb;99:7-17. doi: 10.1016/j.ejpb.2015.11.007. Epub 2015 Nov 25.

PMID:
26625717
21.

Nanoimaging: photophysical and pharmaceutical characterization of poly-lactide-co-glycolide nanoparticles engineered with quantum dots.

Pederzoli F, Ruozi B, Pracucci E, Signore G, Zapparoli M, Forni F, Vandelli MA, Ratto G, Tosi G.

Nanotechnology. 2016 Jan 8;27(1):015704. doi: 10.1088/0957-4484/27/1/015704. Epub 2015 Nov 24.

PMID:
26597894
22.

Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.

Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari Bardile C, Leoni V, Caccia C, Brilli E, Di Donato S, Boido MM, Vercelli A, Vandelli MA, Forni F, Cepeda C, Levine MS, Tosi G, Cattaneo E.

EMBO Mol Med. 2015 Dec;7(12):1547-64. doi: 10.15252/emmm.201505413.

23.

Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts.

Tancini B, Tosi G, Bortot B, Dolcetta D, Magini A, De Martino E, Urbanelli L, Ruozi B, Forni F, Emiliani C, Vandelli MA, Severini GM.

J Nanosci Nanotechnol. 2015 Apr;15(4):2657-66.

PMID:
26353478
24.

Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.

Tosi G, Vilella A, Veratti P, Belletti D, Pederzoli F, Ruozi B, Vandelli MA, Zoli M, Forni F.

Mol Pharm. 2015 Oct 5;12(10):3672-84. doi: 10.1021/acs.molpharmaceut.5b00446. Epub 2015 Sep 1.

PMID:
26312414
25.

Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo.

Chhabra R, Ruozi B, Vilella A, Belletti D, Mangus K, Pfaender S, Sarowar T, Boeckers TM, Zoli M, Forni F, Vandelli MA, Tosi G, Grabrucker AM.

CNS Neurol Disord Drug Targets. 2015;14(8):1041-53.

PMID:
26295815
26.

Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.

Riva G, Lagreca I, Mattiolo A, Belletti D, Lignitto L, Barozzi P, Ruozi B, Vallerini D, Quadrelli C, Corradini G, Forghieri F, Marasca R, Narni F, Tosi G, Forni F, Vandelli MA, Amadori A, Chieco-Bianchi L, Potenza L, Calabrò ML, Luppi M.

Haematologica. 2015 Nov;100(11):e467-70. doi: 10.3324/haematol.2015.126854. Epub 2015 Jul 23. No abstract available.

27.

PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury.

Ruozi B, Belletti D, Sharma HS, Sharma A, Muresanu DF, Mössler H, Forni F, Vandelli MA, Tosi G.

Mol Neurobiol. 2015 Oct;52(2):899-912. doi: 10.1007/s12035-015-9235-x.

PMID:
26108180
28.

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.

Vilella A, Ruozi B, Belletti D, Pederzoli F, Galliani M, Semeghini V, Forni F, Zoli M, Vandelli MA, Tosi G.

Pharmaceutics. 2015 Jun 19;7(2):74-89. doi: 10.3390/pharmaceutics7020074. Review.

29.

PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.

Monsalve Y, Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, Forni F, López BL, Sierra L.

Nanomedicine (Lond). 2015;10(11):1735-50. doi: 10.2217/nnm.15.29.

PMID:
26080696
30.

Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma.

Belletti D, Tosi G, Riva G, Lagreca I, Galliania M, Luppi M, Vandelli MA, Forni F, Ruozi B.

Int J Pharm. 2015 Jul 25;490(1-2):85-93. doi: 10.1016/j.ijpharm.2015.05.029. Epub 2015 May 15.

PMID:
25987470
31.

Nanomedicine and neurodegenerative disorders: so close yet so far.

Tosi G, Vandelli MA, Forni F, Ruozi B.

Expert Opin Drug Deliv. 2015 Jul;12(7):1041-4. doi: 10.1517/17425247.2015.1041374. Epub 2015 Apr 26.

PMID:
25912814
32.

Functionalization of liposomes: microscopical methods for preformulative screening.

Belletti D, Vandelli MA, Tonelli M, Zapparoli M, Forni F, Tosi G, Ruozi B.

J Liposome Res. 2015;25(2):150-6. doi: 10.3109/08982104.2014.956221. Epub 2014 Sep 9.

PMID:
25203607
33.

Poly (D,L-lactide-co-glycolide) nanoparticles loaded with cerebrolysin display neuroprotective activity in a rat model of concussive head injury.

Ruozi B, Belletti D, Forni F, Sharma A, Muresanu D, Mössler H, Vandelli MA, Tosi G, Sharma HS.

CNS Neurol Disord Drug Targets. 2014;13(8):1475-82.

PMID:
25106629
34.

Nanotechnology and Alzheimer's disease: what has been done and what to do.

Ruozi B, Belletti D, Pederzoli F, Veratti P, Forni F, Vandelli MA, Tosi G.

Curr Med Chem. 2014;21(36):4169-85. Review.

PMID:
25039777
35.

Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy.

Pascolo L, Bortot B, Benseny-Cases N, Gianoncelli A, Tosi G, Ruozi B, Rizzardi C, De Martino E, Vandelli MA, Severini GM.

Int J Nanomedicine. 2014 Jun 7;9:2791-801. doi: 10.2147/IJN.S58685. eCollection 2014.

36.

Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release.

Chhabra R, Grabrucker AM, Veratti P, Belletti D, Boeckers TM, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2014 Aug 25;471(1-2):349-57. doi: 10.1016/j.ijpharm.2014.05.054. Epub 2014 Jun 2.

PMID:
24882034
37.

Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport.

Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM.

J Control Release. 2014 Mar 10;177:96-107. doi: 10.1016/j.jconrel.2014.01.004. Epub 2014 Jan 11.

PMID:
24417968
38.

Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.

Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M.

J Control Release. 2014 Jan 28;174:195-201. doi: 10.1016/j.jconrel.2013.11.023. Epub 2013 Dec 5.

PMID:
24316476
39.

Brain targeting with polymeric nanoparticles: which administration route should we take?

Tosi G, Ruozi B, Vandelli MA.

Nanomedicine (Lond). 2013 Sep;8(9):1361-3. doi: 10.2217/nnm.13.135. No abstract available.

PMID:
23987107
40.

Biodegradable device applied in flatfoot surgery: comparative studies between clinical and technological aspects of removed screws.

Ruozi B, Belletti D, Manfredini G, Tonelli M, Sena P, Vandelli MA, Forni F, Tosi G.

Mater Sci Eng C Mater Biol Appl. 2013 Apr 1;33(3):1773-82. doi: 10.1016/j.msec.2012.12.093. Epub 2013 Jan 8.

PMID:
23827635
41.

Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.

Voltan R, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L, Vandelli MA, Zauli G.

Clin Cancer Res. 2013 Jul 15;19(14):3871-80. doi: 10.1158/1078-0432.CCR-13-0015. Epub 2013 May 29.

42.

Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.

Voltan R, Secchiero P, Ruozi B, Caruso L, Forni F, Palomba M, Zauli G, Vandelli MA.

Curr Med Chem. 2013;20(21):2712-22. Review.

PMID:
23627936
43.

Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents.

Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, Forni F.

Nanomedicine (Lond). 2013 Sep;8(9):1373-83. doi: 10.2217/nnm.12.172. Epub 2013 Apr 8.

PMID:
23565661
44.

Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.

Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM.

Curr Med Chem. 2013;20(17):2212-25. Review.

PMID:
23458620
45.

Chemico-physical investigation of tenofovir loaded polymeric nanoparticles.

Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, Ruozi B.

Int J Pharm. 2012 Oct 15;436(1-2):753-63. doi: 10.1016/j.ijpharm.2012.07.070. Epub 2012 Aug 4.

PMID:
22884838
46.

Neurotrophic factors and neurodegenerative diseases: a delivery issue.

Ruozi B, Belletti D, Bondioli L, De Vita A, Forni F, Vandelli MA, Tosi G.

Int Rev Neurobiol. 2012;102:207-47. doi: 10.1016/B978-0-12-386986-9.00009-0. Review.

PMID:
22748832
47.

Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?

Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli MA.

Nanomedicine (Lond). 2012 Mar;7(3):365-82. doi: 10.2217/nnm.11.98. Epub 2011 Sep 30.

PMID:
21957863
48.

The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum.

Bondioli L, Ludovisi A, Tosi G, Ruozi B, Forni F, Pozio E, Vandelli MA, Gómez-Morales MA.

Parasitology. 2011 Sep;138(11):1384-91. doi: 10.1017/S0031182011001119. Epub 2011 Aug 8.

PMID:
21819637
49.

Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.

Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA.

Nanomedicine (Lond). 2011 Apr;6(3):423-36. doi: 10.2217/nnm.11.11.

PMID:
21542682
50.

Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: preparation, characterization and comparative in vitro study with polymeric particles and liposomes.

Belletti D, Riva G, Tosi G, Forni F, Barozzi P, Luppi M, Vandelli MA, Ruozi B.

Int J Pharm. 2011 Jul 15;413(1-2):220-8. doi: 10.1016/j.ijpharm.2011.04.025. Epub 2011 Apr 21.

PMID:
21536117

Supplemental Content

Loading ...
Support Center